PK-enhanced PI-Kinase (PI4K; PI5K) Inhibitors of RNA Viruses
$1,468,743U19FY2016AINIH
Stanford University, Stanford CA
Investigators
Linked publications & trials
Paper 38294906Paper 37581931Paper 37390827Paper 37259914Paper 37180102Paper 36653124Paper 36543117Paper 35982307Paper 35759523Paper 35346346Paper 35189047Paper 35087093Paper 35058616Paper 34551964Paper 34551963Paper 34529084Paper 34193258Paper 34155143Paper 34054824Paper 34017121Paper 34002093Paper 33952674Paper 33871421Paper 33691026Paper 33298607Paper 33173007Paper 33137362Paper 32997652Paper 32576678Paper 32226009Paper 32132525Paper 32064341Paper 31971918Paper 31969487Paper 31945771Paper 31915244Paper 31722210Paper 31562126Paper 31527793Paper 31420268Paper 31384002Paper 31350390Paper 31013272Paper 30935881Paper 30814731Paper 30770827Paper 30768832Paper 30759391Paper 30699342Paper 30646264Paper 30626964Paper 30555904Paper 30413720Paper 30228122Paper 30149262Paper 30135583Paper 30107138Paper 30078634Paper 30043139Paper 29960011Paper 29898768Paper 29888341Paper 29883610Paper 29753658Paper 29706550Paper 29649437Paper 29629118Paper 29618496Paper 29589830Paper 29537985Paper 29535204Paper 29358745Paper 29343568Paper 29337789Paper 29298032Paper 29275860Paper 29241533Paper 29148875Paper 29104927Paper 28942130Paper 28809547Paper 28746868Paper 28692267Paper 28679762Paper 28672171Paper 28662753Paper 28570275Paper 28458037Paper 28420884Paper 28419265Paper 28377596Paper 28331092Paper 28329704Paper 28324666Paper 28306259Paper 28291107Paper 28240606Paper 28076801Paper 28018971Paper 27996937
Abstract
Our goal is to develop broad spectrum, small molecule antivirals with high barriers to resistance against multiple Priority Pathogens. We discovered a novel specific phosphoinositide (PI)-4,5-bisphosphate (PI(4,5)P2, or
View original record on NIH RePORTER →